Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2006 Jan 25.

Published in final edited form as: J Urol. 2005 Aug;174(2):741–746. doi: 10.1097/01.ju.0000164730.38431.5c

SKUB cell line treated with a combination of NV1066 in three different multiplicities of infection (MOI 0.01, 0.05, 0.1) and three dosages of mitomycin-C (MMC-0.1,0.5,1 μGr/ml) at a constant dose ratio of 1:10. Y axis demonstrates the cell kill as calculated by 1% of control cell survival. The synergistic effect of the combined treatment (COMB) at day 4 after treatment is better then each treatment alone.

SKUB cell line treated with a combination of NV1066 in three different multiplicities of infection (MOI 0.01, 0.05, 0.1) and three dosages of mitomycin-C (MMC-0.1,0.5,1 μGr/ml) at a constant dose ratio of 1:10. Y axis demonstrates the cell kill as calculated by 1% of control cell survival. The synergistic effect of the combined treatment (COMB) at day 4 after treatment is better then each treatment alone.